Although cardiovascular diseases are the leading cause of death globally, the number of new therapeutics in development for this disease area have lagged behind others such as oncology and neurology. However, analysis of the current late stage dyslipidaemia landscape reveals that this area may be gaining traction within the industry. This white paper takes a forensic look at recent developments to identify current trends and which near-term compounds look the most encouraging.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: